secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-05-15T12:30:15+00:00
Accession:  0001437749-26-017226
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Q1: Cash $10.3M; MIRACLE trial 40% CRc; 45 subjects enrolled
----------------------------------------------------------------------

- Cash and equivalents $10.3M as of March 31, 2026; R&D expense $5.4M (up $2.0M YoY) on MIRACLE trial costs.
- MIRACLE Phase 2B/3 trial: first 45 subjects enrolled; blinded composite complete remission (CRc) rate of 40%.
- First interim unblinding expected June 2026; 90th subject recruitment targeted for Q3 2026.
- Completed Q1 2026 financings with ~$8.3M gross proceeds; runway extended into Q3 2026.
- Expect to start pancreatic cancer trial in 2H 2026; aiming for rolling NDA submission for R/R AML in 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/0001437749-26-017226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/mbrx20260514_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer